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Introduction
Perinatal substance use continues to be a major public health issue in women’s health. The
purpose of this study was to determine the frequency of substance use screenings in care and
assess how well the existing services in Marin County are serving the needs of pregnant and
parenting women and identifying the gaps and/or weaknesses in current practice.
Methods
Data for this study was collected via semi-structured interviews with five professionals that
worked at the local community clinic, hospital and a non-profit agency. Some questions were
slightly modified to be configured toward the participant’s specific profession.
Results
Results from the interviews reveal common screening practices though some were less formal
and more conversational and there is no technical universal screening tool used. Participants also
noted several common themes in gaps of care, in terms of patient’s views toward health care,
needed improvements, common substances seen, the difference between the hospital and clinic
protocol, adolescents, and African Americans.
Discussion
Findings suggest more training and a cohesive approach to screening should be implemented for
both hospital and clinic settings. More understanding is needed for other care physicians as well
as a need to address the gaps in care for the younger adolescent population, African Americans,
and changing the negative perception of healthcare maternal patients have toward them.
Examining other social determinants of health are also future implications to consider in
perinatal and postnatal care.

Executive Summary
Background & Problem Statement
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Substance use during pregnancy presents multiple adverse health effects on both the
mother and the fetus. Not only does it have detrimental effects on the mother’s health, the fetus
is much more susceptible to long-term or irreversible damage in their development. The
Diagnostic & Statistical Manual of Mental Disorders (DSM-5) defines substance use disorder as
“when the recurrent use of alcohol and/or drugs causes clinically and functionally significant
impairment, such as health problems, disability, and failure to meet major responsibilities at
work, school, or home (Burns, Coleman-Cowger, & Breen, 2016).” In Marin County, a very
affluent area, the prevalence of substance use in pregnant women has escalated over the years,
resulting in harmful effects to women and their fetus. Limited resources are available in Marin to
help mothers receive assistance and treatment with their substance use disorder(s).
It is widely accepted that substance use is discouraged during pregnancy, and women are
encouraged to seek abstinence while pregnant to provide the best childcare for their babies’ first
year (Prince & Ayers, 2019). Only a minor portion of the pregnant population with substance use
issues are identified and treated (Burns, Coleman-Cowger, & Breen, 2016). The most commonly
used substance in pregnancy is nicotine, followed by alcohol, marijuana, and cocaine (Forray,
2016). Vaping is a newer method of nicotine use that has been presumed to be less harmful than
cigarette smoking, although most attitudes think the risk is not worth it for such a vulnerable
population. The continued use of such substances can lead to poor pregnancy and neonatal
outcomes, specifically increased risk of long-term physical, cognitive, behavioral, and academic
problems for children (Muhuri & Gfroerer, 2009). Attitudes about substance use during
pregnancy have varied across medical providers and mothers.
Cannabis
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Cannabis is the most commonly used illicit drug in the US and is the only substance that
has seen significant increases in consumption and prevalence of use in the past decade (Emery,
Gregory, and Levin, 2016). It is the third most commonly used substance during pregnancy
following tobacco and alcohol (Emery et al, 2016). For the mother, there has been an association
between perinatal marijuana use and pregnancy complications such as shorter gestation,
dysfunctional labor period, preterm birth, low birth weights, and stillbirth (Holland, Nkumsah,
Morrison, Tarr, Rubio, Rodriguez, Kraemer, Day, Arnold, & Chang, 2017). For the fetus, there
are neurobehavioral consequences that can follow such as cognitive, learning, and behavioral
problems which can lead to hyperactivity, attention problems, memory, and difficulty with
reading and spelling (Holland et al., 2017). Although there have been adverse consequences,
research is still limited in some areas regarding marijuana use during the perinatal period. The
recent legalization of marijuana in several states over the past few years has likely influenced
many user’s attitudes about its use and find it harmless.
Most pregnant women perceive use of the drug once or twice per week to be of little to
no risk (Scheyer, Melis, Trezza, & Manzoni, 2019). In one observational study, women also
reported that though they received regular obstetric care, they did not receive any helpful
information about perinatal marijuana use from health care providers or social workers
(Jarlenski, Tarr, Holland, Farrell, & Chang, 2017). Because of this, most women stated that they
conducted their own Internet searches for information about perinatal marijuana use and
watching videos (Jarlenski et al, 2017). The lack of information did not bother some women
because some indicated that they had stopped smoking marijuana once they found out they were
pregnant, while others assumed that the providers and social workers did not provide adequate
counseling. This made mothers feel as if marijuana was not a significant concern for the outcome
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of their pregnancy or that it implied its use was not a serious risk (Jarlenski et al, 2017). Mothers
also felt resentment toward social workers because the workers were more focused on child
welfare agencies potentially being involved after the delivery of the baby instead of providing
resources to help women stop using marijuana during pregnancy. This indicates a representative
population of women who take initiative in receiving appropriate care, but not feeling that their
care was fulfilled to prevent use of something they perceive as potentially harmful. Providers and
social workers may not emphasize or educate their clients enough about the importance of not
indulging in the illicit substance.

Alcohol
Alcohol is the second most used substance during pregnancy and no amount is considered
safe during pregnancy (Roozen, Peters, Kok, Townend, Koek, & Curfs, 2018). The US
Substance Abuse and Mental Health Services Administration (SAMHSA) noted in a recent study
that about 5% of entries for treatment services were utilized by pregnant women with low
numbers of them with alcohol issues and higher numbers for other drug uses (Burns et al., 2016).
Drinking alcohol during pregnancy places the fetus at risk for birth defects, growth impairment,
developmental disabilities, and neurodevelopmental dysfunction (Burns et al., 2016). Fetal
Alcohol Spectrum Disorder (FASD) is a common condition that can affect the fetus for mothers
who use, and can lead to poorer mental health outcomes. The severity of FASD depends on the
level, pattern, and timing of prenatal alcohol exposure before and during pregnancy as well as
diet, environmental, maternal age, and genetic makeup factors (Roozen et al., 2018). A study in
Western Australia found that the use of provided educational resources for health professionals
to their patients about prevention of prenatal alcohol exposure, consequences, and FASD was
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effective in their use (Payne, France, Henley, D’Antoine, Bartu, O’Leary, Elliott, & Bower,
2011). Of those interviewed, 69.8% had seen the materials, 77.1% used them, and 48.5% said the
materials helped to change their practice or intention to change their practice (Payne et al., 2011).
Altogether, 91.5% of the health professionals in the study agreed that drinking 5 or more
alcoholic drinks on one occasion would harm the fetus. Ultimately, the study proved that health
professional’s knowledge increased with the use of the materials and change in attitudes
surrounding FAS and advice they give to pregnant women about consuming alcohol. In
Australia, most providers in a particular study (88.1%) believed that pregnant women should
avoid alcohol and those planning to become pregnant in the future should abstain (78.2%)
(Payne et al., 2011).
There are several screenings that providers are recommended to use to screen their patients,
including the Cut Down, Annoyed, Guilty, and Eye Opener (CAGE) and Alcohol Use Disorders
Identification Test (AUDIT) (Prince & Ayers, 2019). These were general screening tools that
were not specified for pregnant patients, therefore an obstetrician developed the T-ACE/TACER-3 and it was validated by the American College of Obstetricians and Gynecologists
(ACOG) as well as the National Institute on Alcohol Abuse and Alcoholism. The obstetrician
based the T-ACE on three questions assessing a patient’s annoyance with criticism of her
drinking, her requirement of eye openers, and her alcohol tolerance (Prince & Ayers, 2019). The
CDC also recommends using the Behavioral Risk Factor Surveillance System (BRFSS) to assess
alcohol use among pregnant women (Burns et al., 2016).
Vaping
Electronic cigarettes (“e-cigs”) also known as vaping, have become increasingly popular as
smoking rates have decreased. Traditional cigarette smoking during pregnancy is linked to
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increased risk of miscarriage, cleft lip/palate, premature birth, and SIDS following birth
(Whittington, Simmons, Phillips, Gammill, Cen, Magann, & Cardenas, 2018). The development
of newer electronic nicotine delivery systems (ENDSs) are newer tobacco products that were
introduced to the US in 2007, including, hookah, vape pen, vaporizers, and electronic cigarettes
(e-cigs) (Whittington et al., 2018), Overall perceptions of ENDSs for pregnant women and
general smokers are that they are less harmful than traditional cigarettes, which has increased
their motivation to quit traditional cigarettes or reducing cigarette smoking (Whittington et al.,
2018). One survey reported that of 252 OB/GYNs, fewer than 53% consistently screen patients
for exposure to tobacco products, which may contribute to the reasons that there are limited
research on the effects of vaping (Whittington et al., 2018).
Participants that posted in an online forum discussing nicotine use thought symptoms of
nicotine withdrawal by pregnant mothers cause too much stress and that abrupt cessation is
unsafe and unhealthy for women and their babies (Wigginton, Gartner, & Rowlands, 2016).
Harm reduction is necessary, and posters within the forum thought that providers should enforce
and emphasize this more in care. They also viewed vaping as less harmful and safer and that it
could be managed by the smoker (mother) to be able to eventually cease use. Ironically, medical
practitioners were described as supportive of vaping per their own personal claims (Wigginton et
al., 2016).
Attitudes Surrounding Substance Use
Provider and Maternal Perceptions
It is critical that medical professionals receive appropriate and competent training in
screening patients. One study (Oser, Biebel, Harris, Klein, & Leukefeld, 2011) showed that
gender difference had an influence on OB/GYN’s screening practices, with female practitioners
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more likely to believe in the effectiveness of screening and discussing sensitive topics with
patients, and motivated to provide screening as a part of care because they believe screening
could produce a behavioral change. Another study highlighted how obstetric providers were not
familiar with risks of marijuana use in pregnancy, perceived marijuana to not be as dangerous as
other illicit substances, prioritized other counseling topics, and mentioned a need for more
information and training on addressing perinatal marijuana use overall (Holland, Nkumsah,
Morrison, Tarr, Rubio, Rodriguez, Kraemer, Day, Arnold, & Chang 2016). When and if
providers did counsel patients on use, their primary approach was the legal consequences or
involvement of child protective services, which may explain many patients’ fears to disclose
their substance use status (Holland et al., 2016). Another reason that may explain the
underrepresentation of mothers disclosing their use status is from mothers who reported they felt
guilty and remorse of use and the fear of the loss of their children out of home care (Burns et al.,
2016). Women also reportedly have many perceived concerns and/or risks in disclosing their
substance use, specifically feeling embarrassed and guilty about use, fearing imprisonment,
prosecution, or losing custody of their child/children (Chang et al., 2018). Prior research suggests
that pregnant women with substance use disorder(s) consider testing and reporting of their use to
be punitive rather than potentially helpful or resourceful (Jarlenski et al., 2017). These
implications altogether portray mothers’ legal concerns and of the repercussions, stigma, shame,
and fear of being viewed as a “bad mother” as well as a need to address women’s mental health
regularly during pregnancy to ensure she is supported.
Recommendations/Treatments
Healthcare professionals are a significant contributor to the concept of harm reduction
especially within the realm of alcohol consumption for pregnant women. They are considered to
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be the best source of information and should have expert advice especially during the perinatal
period, therefore should be prepared with effective education materials (Payne et al., 2011). The
ACOG and the American Academy of Pediatrics recommend that clinicians caring for pregnant
women ask their patients at their initial prenatal visit about their drug use and provide education
(Chang et al., 2017). The questions they ask should be presented in a nonjudgmental manner, to
increase trust that is needed to obtain an accurate history and to retain mothers for ongoing care
(Burns et al., 2016). The World Health Organization (WHO) recommends engaging women in
improving their mental health before becoming pregnant since women are at the highest risk of
substance use disorders during their reproductive years and mental health problems are most
prevalent at childbearing ages (Prince & Ayers, 2019). This ensures women will achieve
psychiatric stability and reduces negative mother and fetus outcomes. A study found that an
integrated care approach for mothers resulted in many finding the environment safe and
welcoming which allowed them to be more forthcoming about their issues and establish trust
with providers, more access to care, women felt supported, and program engagement and rapport
increased (Marcellus, MacKinnon, Benoit, Phillips, & Stengel, 2015).
Additionally, OB/GYN’s should be advocates for patients and education for not only patients
but also providers is necessary to continue with the unknown, yet possible harmful effects of
ENDSs and to help prevent fewer toxins being exposed to fetus and mom (Whittington et al.,
2018). Though clinical evidence suggests that e-cigs are safer than smoking, there are still many
concerns surrounding long-term effects for fetal development and online forums suggested that
women refrain from them altogether (Wigginton et al., 2016). Pregnant women using cannabis
should be offered support for cessation and relapse prevention at each prenatal visit throughout
pregnancy (Burns et al., 2016). Asking a mother about her perceived level of severity can create
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discussion about other problematic areas such as trauma and abuse, with special attention to high
risks, as well as brief intervention, counseling, education, and psychologically based treatment
for dependency. The 5 A’s approach (Ask, Advise, Assess, Assist, and Arrange) is also a wellknown tool to use for cases related to tobacco use and is recommended by the United States
Preventive Services Task Force (USPSTF) and the ACOG though more intensive interventions
may be required (Burns et al., 2016).
Supervised detoxification may be necessary for those with more severe alcoholism, likely
as an inpatient (Burns et al., 2016). Many pharmacotherapies available for alcohol dependence
are contraindicated for pregnant women, yet withdrawal can lead to fetal distress and/or death.
There is a specific need to focus on psychological and social approaches with assertive follow-up
throughout and post pregnancy (motivational interviewing). Patient-provider communication is
essential to care, with other interventions including counseling by midwives, screening via
nonmedical community workers, and multimedia and educational efforts aimed to improve
knowledge (Forray & Foster, 2015). There is clear evidence of the negative effects of alcohol,
tobacco, and illicit drug use being harmful during the perinatal period, though vaping and
cannabis use still needs to be thoroughly researched.
Agency Profile
The County of Marin’s Department of Health and Human Services (HHS) is a
government entity that strives to promote and protect the health, wellbeing, safety, and selfsufficiency of all people in Marin. They are the largest department in Marin County and
currently have four divisions: planning and administration, behavioral health and recovery
services, public health, and social services.
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The public health department features an executive staff that is led by the Director of
Health and Human Services, a Behavioral Health and Recovery Services Director, a Social
Services Director, and a Public Health Officer. The Department is situated at the Marin Health
and Wellness Campus in San Rafael, which features a variety of services for the public including
a community clinic, all in one location. It was funded from a master settlement agreement to
address Marin’s most critical health needs. The Connection Center is the heart of the campus and
is host to many of the programs and services provided to the community. It is known as the
center point for health promotion, prevention activities, meetings, and contact information
needed for other county services. There is a vast bilingual and multicultural staff who assist the
public for case management, billing services, health insurance enrollment, referrals, and
assistance accessing services. To address risk factors that affect health and quality of life, the
Connection Center has educational materials in English and Spanish and LCD screens that
exhibit topics that feature health-related activities. The topics were chosen via community focus
groups and meetings as well as input from HHS staff.
The Maternal, Child, and Adolescent Health (MCAH) Program is a subsidiary program
under the County of Marin’s Family Health Programs. The program develops prevention and
early intervention strategies to promote the health of the women, infants, children, and
adolescents of Marin County with a special focus on low-income and vulnerable populations.
MCAH program staff is involved in outreach, advocacy, policy development, assessment, and
program planning to increase access to family-centered, culturally-competent systems of health
services. The agency is headed by a director and program coordinator. Within the department,
there is the Women, Infants, and Children Program (WIC), Marin Family Connections, Child
Health Disability Prevention (CHDP), CA Children’s Services (CCS), and the Childhood Lead
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Poisoning Prevention Program (CLPPP). Each service aims to serve families by achieving equity
for families and children to have access to the best services for a healthy, safe, and productive
life. The Behavioral Health and Recovery Services unit also works closely with MCAH and
provides resources to refer clients to behavioral health services to specialists such as clinicians
and/or other therapists as needed.
Project goals and objectives
Originally, the two main goals of this project were to identify gaps in the system of care
for pregnant and parenting women with SUD’s in Marin and to develop an updated, specific
resource directory for mothers/expecting mothers who are experiencing SUD’s and for
service/clinical providers to use (Appendix A). The initial plan was to interview pregnant and
parenting mothers, but proved to be tricky to conduct interviews. Ultimately, it was determined
that professional providers within the wellness campus would be easier to outreach to and could
have just as much thorough insight and experience with their patients. Conducting interviews
were delayed due to the difficult impact of the coronavirus pandemic. Outreaching in
conjunction with my preceptor to potential participants was delayed until the pandemic calmed
down (around June), but five were able to be completed instead of the original 10-15 interviews.
Though a draft of a resource directory was made and to be edited after interviews
(Appendix F), it was saved on the fieldwork site computer and unable to be accessed due to the
coronavirus pandemic and shutdown of the facility. Around mid-March, restrictions were put in
place that prevented anyone from going to their workplace. There were also plans to create new
and updated educational materials to be available on the wellness campus and within the clinic as
a secondary goal but was also unable to access. The draft lists specific providers and agencies
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that are known in Marin to assist with pregnant and parenting mothers. Due to its inaccessibility,
the final draft was unable to be completed.

Methods
Objective
The purpose of this project was to understand the prominence of screening for substance
use in parenting and pregnant mothers in Marin County and the gaps in care mothers do not
receive. For this project, a qualitative analysis was used to determine the frequency of substance
use seen in screenings done by providers and staff perspectives on the issue. Another task was to
see what services were not available and what providers and staff viewed as a necessity to the
community.

Sample
Five healthcare professionals (perinatal case manager, substance abuse counselor,
obstetrician, and two pediatricians) that worked at the local Marin Community Clinic and local
organizations were purposefully chosen via purposive sampling from my preceptor’s
recommendations. These recommendations were based on the relevance of the provider and staff
experience because of their interests in women’s maternal health per the MCAH’s close work
with them.
Recruitment
An introduction email (Appendix B) was sent to potential participants via the MCAH for
the project and outlined the goals and purpose of the interview. Out of twelve participants that
were emailed, two emailed back with contact information the same day and were interviewed.
One of the participants additionally forwarded the email to seven other providers that were
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knowledgeable about perinatal substance use in the community. Of those participants that were
forwarded the introduction email, three were interviewed. Two participants had great
connections within their organization and forwarded the original email. Phone calls were made to
each participant as they provided them via email along with their availability. Due to the
coronavirus pandemic and shelter at home orders from the state, participants that were emailed
but did not respond likely had restricted availability or were too busy dealing with other
significant changes.

Procedure
Semi-structured interviews were conducted via phone calls with a 12-question item
survey for providers and staff to answer. The length and scheduling of interviews varied for
provider’s availability and staff within a three week time frame. Interviews lasted an average of
30-45 minutes per session. Purposive sampling was used to recruit participants based on the
MCAH director’s close network and relationships with providers that often work together. All
providers listed references on other prospective participants during the interviews and often cross
referenced each other.
Measures
A 12-item questionnaire (Appendix C) was created and used based on the influence of
one study’s use of a questionnaire from a Washington Health Department that used a 10-item
questionnaire (Oser, Biebel, Harris, Klein, & Leukefeld, 2011). Though the original article was
inaccessible to use their specific items, questions were modified as described from Oser and
colleagues’ (2011) measures section. The dependent variable was how regularly providers screen
for substance use and if they do at all. The independent variables were motivations for
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screenings, if they felt there were enough resources for perinatal substance use, and if screenings
would help effectively promote a positive behavioral change for their patients.
The interview tool used was modified with suggestions and authorized to use from the
MCAH director. Ultimately, the questions were placed in order of focusing first on screening,
then referral and motivational interviewing, and finally treatment resources. The questions were
also edited to more open-ended questions to obtain significant data for each response. Responses
were recorded via notes typed using Microsoft Word during the interview. After each interview,
notes were highlighted to review themes and develop best practices in addressing substance use
in pregnant and parenting mothers.

Challenges
Some of the challenges that arose were availability of the staff due to the coronavirus
pandemic and shelter at home enforcement. There was also limited data received during some of
the interviews due to different professions and their approaches in care based on their
background. The quality of the answers from each question mostly were thorough and enough
information was able to capture a satisfactory general depiction of the frequency of substance use
in mothers who struggle. Resources were also provided and all participants stated what they felt
was missing or lacking and had some feedback and insight from other program methods and on
what is needed in Marin. A codebook was created and dissected using the qualitative analysis
software N-Vivo to interpret and find themes.
Goals of the Interviews
Some of the main goals of data collection were:
1. To identify barriers in care for pregnant/parenting mothers with SUD's
2. To determine the frequency of screenings from provider perspectives/protocols
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3. To identify motivating factors that make providers conduct screenings
4.

To identify resources needed in Marin for more maternal support

Interview Results & Data Analysis
Qualitative data analysis using the N-Vivo software platform grouped together several
common themes that were identified. The definition for each theme (Appendix E) was used to
group similar ideas and attitudes in order to identify major themes.Findings were summarized in
identifying common screening protocols and addressing the gaps in care as well as resources
currently available and needed within Marin.
The top themes (Appendix D) that participants noted in identifying barriers and resources
needed for mothers with SUD’s were necessary areas of improvement, review of screening
practices and protocols done and more outreach to adolescents. All of the participants mentioned
areas of improvement that needed in care of pregnant and parenting mothers with SUD’s and
within their own working systems, as well as a need to better serve African American mothers
and have better universal screening practices. Few positive interactive experiences were
reported, primarily only on what participants viewed what a positive interaction would be
perceived as in their opinion.
Emergent Themes
Areas for Improvement
Every participant had commentary on areas of improvement needed in their work
environment as well as commentary on procedures and programs they wished to see in the
community. One provider noted how they “would love to change how they help manage
substance use in the neonatal, postnatal care period. Whatever they could do to help that would
be very beneficial especially for the bonding time, also consider working closer with pediatrics
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who helps check the baby, nursery, mother, etc.” The next provider mentioned she wanted to
adopt an approach that other hospitals were using, where they “moved toward keeping mom and
baby together for bonding. In the postpartum period, she is interested in wanting to know how to
help mothers who have substance use disorder(s) and how more support could be provided to
reduce stigma and provide better and more competent care for their issues as well as partner with
other outside organizations to help” as well. Another significant barrier mentioned was that
“programs should be more accessible programs for mothers with postpartum depression, because
they are expensive and can be hard to access. More Spanish speaking groups should be
considered.” The protocol in the clinic’s screening was addressed, with one provider stating they
would “love to see the clinic ending the use of urine toxicology testing because it does not serve
nor benefit patients” which also may contribute to stigma and pregnant/parenting mother’s
resistance to treatment.
One provider also mentioned that there was a lack of diversity as far as gender-based
services, stating that there were “very male dominated treatment centers” which could also affect
services. The same provider also mentioned significance in the “lacking support for transwomen
and women experiencing homelessness” which could also explain more barriers to having
accessible treatment in terms of socioeconomic and gender identity status.

Screening Practices
The AUDIT-C was the only main professional screening tool (SAMHSA) that formally
addressed a specific SUD. Another provider disclosed that they followed the SAMHSA
guidelines and memorized the NIDA-Modified tool to identify risky substance use in their adult
patients. Verbal and conversation screening practices were accounted for and notated in all
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participant responses, most clarifying they did not use a specific tool per say, but
conversationally were able to screen their patients. Both pediatricians noted they used the
HEADS assessment, which is tailored toward adolescents and focused on the least threatening
topics then later getting to more sensitive topics.

Adolescents
Three participants noted the lack of care and support in addressing adolescent audiences
and prenatal care. Two participants were unsure of the full scope of OB/GYN practices since it
was not their field of medicine. Both providers also believed “meeting adolescents where they
were at” was essential to help in screening, specifically with the use of wellness centers that were
available on campus at one local high school. The same participants also mentioned the local
teen clinic “Huckleberry Youth Programs” that primarily serves adolescents was a huge indicator
of support and positive response in decreasing SUD’s and pregnancy in younger teens.
Huckleberry’s mission is to educate, inspire, and support underserved youth to develop healthy
life choices, to maximize their potential, and to realize their dreams (Huckleberry, 2020).
Common Substances Used
All participants provided substances that they commonly seen or have come across
during their professional years in dealing with patients. There appeared to be a consensus of
marijuana, tobacco, and alcohol being the most common substances mothers disclose that are
mentioned during care. As one participant stated, “the most common ones that patients disclose
willingly are alcohol, tobacco and marijuana. Patients say during pregnancy occasionally they
have had alcohol and tobacco. Some patients say before pregnancy they were using alcohol or
smoking but quit once they found out they were pregnant.” This suggests differences in opinion
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that mothers perceive the potential harm and effects that substances have on the mother and their
fetus.
A participant noted how younger audiences perceived substance use during pregnancy
and stated how “pregnant teens perceive drinking during pregnancy is bad. Instead, they vape or
orally take THC thinking that it is safer” which may contribute to differences in opinion across
age groups. Participants hinted at the point that the legality of marijuana during recent years may
have also decreased stigma towards its use even for mothers. Only one participant mentioned
that “they do not screen for drugs unless the client shares that with them.”
One participant noted that there was a change in recent years, where “meth and heroin
were past issues that were prevalent previously.” Another participant also commented similarly
saying “meth and opioids are the most common ones for illegal ones bought on the street but it is
not as much of an issue as other less harmful substances.” Methamphetamine, cocaine, heroin,
and fentanyl were uncommon and were often referred to outpatient services when it was
previously a prevalent issue within the maternal population.

Negative Perception of Healthcare
Almost all providers were aware of and contributed to their reasoning why mothers do
not seek assistance with their SUD’s or help overall for treatment. One provider noted that the
“healthcare does not promote harm reduction or well-being enough. They too heavily focus on
punishing and penalizing people.” Another professional discussed the child welfare systems and
how they “make it challenging to conduct screening and have good conversations about
substance use. Many people have distrust in the healthcare system because of it” especially for
vulnerable populations. The main barrier addressed that three providers discussed was stigma
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around substance use, which was very huge. One health professional mentioned that “lots of
pregnant people that are using are aware of how stigmatized they will be and are fearful of being
judged, being a bad mother/parent, being seen as the opposite of what a good mother is and that
there is just lots of pressure for moms, which keeps them from wanting to disclose their SUD or
substance use status altogether.”

Hospital vs. Clinic Environment
Some positive impressions were expressed over the clinic’s services than the hospitals.
Two providers mentioned the clinic has “great communication and referrals often are made
within the clinic” and how they have a “robust behavioral health department connecting patients
to the behavioral health team.”
Evidently, there were several inconsistencies made between the hospital and clinic
environment regarding protocols and patient care. One provider mentioned the difference, that
“at the hospital, OB/GYNs are all over the place with screening, because they “know” their
patients, whereas MCC has one protocol.” Similarly, the next professional mentioned that “she
works at the hospital and during pregnancy there is heterogeneity within the OB/GYN providers
because some are testing and following the recommended guidelines, but some are not. She has
seen at-risk women go to OB/GYN practices and not be screened for drugs at all.” Another
professional mentioned how “MCC has a very diverse environment in terms of patients and who
they serve but separate from the hospital because the hospital is an unjust environment and
features a lot of benefits for wealthy white patients, while patients on Medi-Cal or Medicare do
not receive the same benefits.” Bias appears to be significant and evident in terms of the
differences between the hospital and clinic from professional perspectives.
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African Americans
Consensually, three participants mentioned that the African American community was
not properly served in Marin, especially in healthcare. One person mentioned that “the system
disproportionately targets people of color, especially black people and indigenous persons.”
Another informant noted the significance of having a leader or someone representative of your
own group. The explanation was that “there is likely a lack of care especially for black patients
because few providers are not a reflection of them, which leads to lack of trust. That is a longterm hurdle and negative issue that the clinic and hospital have in serving them in Marin and
why they likely are not served as well.” People of color in Marin have long experienced
discrimantion and more needs to be done to provide patient-centered care and ensure
competency training continues.

Discussion & Implications
Altogether, providers should be competent in care for mothers with SUD’s just as much
as any other patient. Cultural competency training should continue and be visible as the resource
directory already has implemented. Mutually, all participants gave insight on a need for a
universal screening protocol and an interest in more training and understanding more patient-care
approaches to addressing the subject with patients. A genuine interest and curiosity in
progression and improvement in care was apparent, and an interest in the effects of vaping was
also common. The more common substances such as marijuana and alcohol appeared to be the
most common substances that professionals encountered in the pregnant and parenting mother’s
population as well as a need for more services. It was noted in two providers that in previous
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years, for other common illicit drugs such as methamphetamine and heroin were prominent
substances abused but has lessened over the years, which was a positive outcome. Two providers
also alluded to other factors such as trauma and domestic violence and how they may coincide in
terms of substance abuse and women’s health. It could also attest to how those factors address a
need for necessary care needed for women with those struggles, especially in mental health.
Those interested in women’s health and maternal care would benefit from this study’s purpose
and reviewing the need for their populations and how to be proactive in discussing this with
women.
Patients and their providers should be able to maintain a solid foundation and relationship
which would help continuity of care and a better perspective overall with the healthcare system.
Trust and rapport with a provider are also significant factors for mothers with SUD’s to continue
care to reduce those stigmas of being a bad mother, fear of losing custody of their children,
embarrassment and guilt, or being fearful of punitive repercussions (Burns et al., 2016). Gender
and identity should also be considered, though a couple of participants noted the fact that there
was a lack of diversity as far as people of color and male versus female dominated treatment
centers. Only two participants mentioned the use of a formal screening tool (AUDIT-C and
NIDA) with one being used as an incentive for insurance purposes and the other being used
through their training. More SAMHSA guidelines should also be considered for practice in
healthcare and counseling sessions. Future studies could show the significant changes in care
after professionals are educated on different screening tools then a follow up interview on how
effective the tool(s) are or if they ended up adopting one.
Some of the strengths of the study were having providers that work concurrently within
the hospital and clinic and having providers with a dual perspective in each environment. Not
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only were they familiar with the procedures for each, they also were familiar with the systems
that other healthcare professionals engaged in and did not hold to a higher standard. Having a
concrete concept on the differences between care in the hospital and clinic is also vital for the
possibility of integrated health models. Cultural competence training was also included in the
directory in terms of the provider having completed training or not. Cultural competency training
increases awareness and knowledge on topics on diversity and inclusion. Having this displayed
on a resource may also increase a mother's faith that their care is being treated by a professional
who appreciates them without judgment or bias.
Some of the limitations of this study were not interviewing male providers and health
professionals, as well as not interviewing primary care physicians. Another limitation was not
having designated questionnaires for each provider (OB/GYN, counselors, social workers, etc.).
Another good population that would have been a good idea to interview and have a tool for
would be primary care physicians (PCP) specifically for those who see parenting mothers that
are already raising their children and/or expecting to have more children. This would gage
attention towards the mother’s use and view the protocol done by PCP’s for screening and
assistance. Purposive sampling was used to recruit participants based on the MCAH director’s
close network and relationships with providers that often work together and to focus the project
on clinical and service providers. Purposive sampling is when a researcher relies on his or her own
judgment when choosing members of a population to participate in the study.

For this study, no staff from rehabilitation and treatment centers were interviewed. A
clinical perspective would have given more insight on treatment. More specifically, the Marin
Treatment Center and Center Point were both mentioned by three providers as follow up services
that they were aware of available for women. Center Point would have been a good resource of
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information especially because one of their programs focuses on women and children. Per their
website, “70% of the women remained employed and reunited with their families following
completion of the program; over 90% remained abstinent and free of child welfare involvement;
over half had regained custody of their minor children; and more than 85% were employed and
had secured stable housing (CenterPoint, n.d).” Some of these other social determinants of health
should be considered and used in future studies as well. Because of the impact of the 2020
coronavirus pandemic and stay at home orders, the study was presumed to be limited to essential
workers but providers were unavailable due to busier schedules and likely adjusting to the new
norm from the mandates. Having a perspective from mothers would also likely have created a
better snapshot of support needed and a perspective on their end of healthcare and their
experiences.
Another limitation was that providers were all female and it was a very small population
of participants to interview. Due to the timing and because of COVID-19 as well as state and
local restrictions, it was understandably a struggle to recruit participants and added to having
some limited results. Having a more variety in other health professions that often deal with the
pregnant and parenting mothers' population may have presented an array of other issues and
barriers to address as well as more ideas for improvement and organizations to consider or
implement in Marin.
Recommendations
In terms of screening, there are many recommendations the pediatricians expressed that
their universal screening is incorporated and universal with younger teens, therefore could be
merged into one question. Marin needs to promote further education that should continue to be
displayed and placed at the forefront of prenatal care and screenings should be universal to

Running Head: PERINATAL SUBSTANCE USE IN MARIN

25

incorporate a holistic approach. An adult version of the HEADSS assessment should also be
considered to implement in pre- and post-natal care. To decrease stigma, attention should not
solely be focused on the mother’s SUD(s) but her mental, emotional, and physical well-being.
One participant noted that question 8 on the questionnaire about “programs that they wished
were available” should be tailored to patients because they likely have a better perspective on the
needs in their own community. This may likely positively correlate with a need for more support
groups, whether in a physical or online forum format that should be considered for women to
express their concerns and wishes for help.
It is essential that other healthcare professionals be engaged in the severity of SUD’s
within the pregnant and parenting mother's population and having a proper, universal method to
assess and assist in their care. The ACOG and the AAP both recommend that clinicians ask their
patients about their substance use at their initial visit, and should continue thereafter, especially if
a mother shows more risks (Chang et al., 2017). Education on the potential risks and harms
substances have on the fetus and the mother should be presented and reminded to patients at their
prenatal appointments as well as assessing risks of the mother’s SUD’s and giving a warm hand
off within the clinical setting as stated by current providers. SAMHSA currently offers a guide
called the Clinical Guidance for Treating Pregnant and Parenting Women With Opioid Use
Disorder and Their Infants that can be utilized during prenatal sessions and they also have
suggestions on how to help treat mothers on various substances (SAMSA, 2020). More training
workshops should be held focused on substance use during pregnancy and the negative harms it
has on both the fetus and the mother. Wellness training should also be considered for health
professionals to target pregnant and parenting mothers and create a harm reduction approach in
care for women. Group sessions or a local conference with local providers may present a
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cohesive plan to create a universal screening approach that providers and counselors may find
useful to implement in their practice setting. As previously stated, patient-provider
communication is essential to this population to improve knowledge and education to help
reduce the chances of use during pregnancy (Forray & Foster, 2015).
Marin appears to be lacking in support and care for younger teens and mothers with
SUD’s, as well as for women of color, especially African American women. Programs should be
implemented in focusing on youth and policy should be focused on a universal approach for
screening in both the clinic and hospital setting. Providers should be on the same page to
maintain consistency in screening for both the pre- and post-natal period to reduce bias in their
patient populations and consider having a more diverse workforce since that was a primary
concern. Other professional and evidence-based screening tools, such as the 5 A’s or the BRFSS
assessments should also be considered in Marin to determine the most effective and ways to
determine a pregnant or parenting mother’s risk and SUD status to receive the best care possible
that can be provided.
Pregnant women experience many struggles mentally, physically, emotionally and
socially with pregnancy. We cannot assume that all their issues are visible. With compassionate
integrated care, proper screening protocols, resources, and support, we can help destigmatize
mothers with SUDs and promote healthier outcomes for themselves and their children.
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Appendix A:
Goals & SMART Objectives

Goal:

Parameter

1. To identify gaps in the system of care for pregnant and parenting
women with SUD’s in Marin.
● By April, I will have contacted at least 10-15 providers that
have direct perinatal specified services.

Specific

● Create an interview guide
○ Start & End Date: March 2020
○ Tracking measure: create a list of questions that will
be approved by preceptors
● Email providers and schedule phone interview
○ Start & End Date: March 1-April 30th, 2020
○ Tracking measure: book interview on a calendar
● Ask questions conducive to new ideas surrounding services
specifically for pregnant and/or parenting mothers
○ Start & End Date: March 1-April 30th, 2020
○ Tracking measure: notes taken from interview

2.

To develop a specific resource directory for mothers/expecting
mothers who are experiencing SUD’s and for service/clinical
providers to use.
● By the end of spring semester, I will have a completed
resource/provider directory tailored to expecting or current mothers
that are experiencing SUD’s
● Create a draft of current resources available for moms
○ Who is responsible: BW
○ Start and End Date: January 31 st-May 2020
○ Tracking Measure: completed initial draft of current services
● Integrate other local sources that may offer specified
services/accommodations for moms
○ Start and End Date:
○ Tracking Measure: completed initial draft of current services

Measurable
Achievable
Realistic
Time-framed
Specific
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● Create at least 2 updated educational pamphlets that mothers can
use
○ Start and End Date: January 31 st-May 2020
○ Tracking Measure: approval from SR/JS to be able to leave
in public areas around the health and wellness campus

3. To learn about the frequency of screening substance use during the
perinatal period for mothers in Marin.

Measurable
Achievable
Realistic
Time-framed
Specific

● By the end of spring semester, I will have learned about
several screenings that providers use for mothers who abuse
substances during and after pregnancy.
● Attend at least three Maternal Child, Adolescent Health
(MCAH) meetings for community perspective on maternal
care
○ Start & End Date: 2/1/2020-7/1/2020
○ Tracking measure: maintain attendance record with
SR
● Conduct interviews with OB/GYN or other providers who
screen mothers
○ Start & End Date: 3/6/2020-3/27/2020
○ Tracking measure: notes from interview, answers to
questions asked
Measurable
Achievable
Realistic
Time-framed
Appendix B:
Hi friends- we are very interested in improving the system of care for pregnant and parenting
women who use substances. Our fabulous intern, Breanna Williams, will be conducting key
informant interviews (by phone) with perinatal service providers to learn more about your
screening practices and about the gaps that exist in the system of care. We would be very grateful
if you could participate in a 15-20 minute phone interview in the near future.

Running Head: PERINATAL SUBSTANCE USE IN MARIN

32

Breanna's introduction: Hello, my name is Breanna Williams and I am a graduate student at the
University of San Francisco. I am studying to receive my Masters in Behavioral Health and
Public Health. I have been conducting fieldwork for my capstone due this August. I am currently
working with the County of Marin Maternal Child & Adolescent Health program focusing on
perinatal substance use in Marin. This interview should last about 15-30 minutes. You are
welcome to skip any question you do not wish to answer and if needed, you are welcome to end
the interview at any time. No identifying information will be provided in my report and will
remain confidential. All the information provided will be used to understand the frequency and
importance of screening, and to identify gaps in the system of care.
1) Please contact Breanna cc'd above with your phone number and availability ASAP.
2) Please forward this request to community partners or others within your agency whose input
would be valuable, or send suggestions for people to include who might be involved in doing
substance abuse screening and/or referrals for this population.
3) We will make the findings available to all participants.
Appendix C:
Interview Guide
Research Question: How regularly do providers screen for substance use in pregnant or parenting
mothers and what conditions motivate them to?
Key Informant Interview Questions:
1. Do you routinely screen your patients for substance use?
2. What prompts you to conduct a screening? What makes it challenging for you to conduct
screening? (What specific concerns do you have about screening?)
3. Do you use a screening tool?
a. Yes: Which one(s)?
b. No: Have you heard of CAGE, T-ACE, TWEAK, 4 P’s or considered using any
of them?
4. What are the most common substances that women screen positive for? What are the
most common illegal substances that women are using? What are the most common
substances women are voluntarily seeking treatment for?
5. What are barriers to screening pregnant and parenting women for substance use in your
setting?
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6. Do you feel comfortable with motivational interviewing?
7. What are some referrals and/or programs available that you refer pregnant women to?
(can be local or further)
8. Are there any other programs you wish were here in Marin to support mothers with
SUD’s? (can be one you know, have seen, or found via research, word of mouth)
9. Which populations are not well served by existing resources? (teens, non-English
speakers, immigrants, low-income, POC, etc.)
10. How does your organization address co-occurring disorders among pregnant women,
such as depression, anxiety, suicidal thoughts, etc.?
11. Is there anything else you’d like to contribute regarding perinatal substance abuse
screening, referral, or treatment?
12. Who else would you consider a good contact to discuss this issue with? (providers,
organizations, etc.)

Appendix D:
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Appendix E:
Name

Description

Files

References
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Adolescents

African American

Areas for Improvement

Common Substances
Used

Hospital vs Clinic
Environment

Negative Perception of
Healthcare

Positive Interactions

Screening Practices

anything pertaining to the
adolescent group of
women at childbearing
age
any referral to Black
Americans, ethnic group
of Americans with total or
some ancestry from any
of the black groups in
Africa
anything that was
included that participant
is interested in
implementing, improving
services and making them
more accessible, services
or protocols that should
be provided or could be
worked on for pregnant
and parenting mothers
anything relating to the
most common illicit or
legal substances used,
seen, or disclosed in
screenings with pregnant
and parenting mothers
differences or similarities
as far as protocol, beliefs,
etc. in the hospital and
clinic environment
anything related to the
negative perspectives,
beliefs, or experiences in
healthcare that causes
pregnant or parenting
mothers less chance of
seeking healthcare
relating to the
significance trust and
rapport of building
relationships with patients
and what constitutes a
good relationship with a
provider
current practices or
screenings used when
seeing patients
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Provider

Service
Type

Population Cultural
(s) Served Capacity/Speci
alty

Bay Area
Commun
ity
Resource
s

General
Outpatie
nt

Adult
Women
(18+)

Center
Point Inc

Marin
Treatme
nt Center

Languag
es
Spoken

GenderSpecific
(Female)

Intensive Perinatal
Outpatie
nt
Resident Adult
ial
Women
(18+)

Pregnancy

Perinatal

Pregnancy

Adult
Women
(18+)

Medication
Assisted
Treatment

Opioid
(Narcotic
)
Treatme
nt
Program

36
Address

Contact
Informati
on

Hours
of
Operati
on
MonThurs
8:30AM
-4PM

Basic/Limit
ed
Disability
Access
Basic

103 Shoreline
Pkwy
San Rafael, CA
94901

415-3286269

415-4566655

24
hours/7
days

Basic

415-4573755

Dosing
Hours:

Basic

www.bacr.org
GenderSpecific
(Female)

Protected
San Rafael, CA
www.cpinc.org

Spanish

146 Lincoln
Ave, San
Rafael, CA
94901

M-F
7AM11:30A
M

Perinatal
www.mtcinc.o
rg

Sat/Sun:
7:45AM
10:30A
M
Holidays
:
9:30AM
-10AM
AGENCY DIRECTORY

PROVIDER DIRECTORY
BAY AREA COMMUNITY RESOURCES
Last Name

First Name

License

National Provider
ID #

License #

Completed
Cultural
Competence
Training?
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Coleman

Michael

Cosby-Frost

Amy

Goldstein

Steven

Kantarowski
Meneweather

Laura
Leslie

Milton

Paul

Rexford

Brittney

Williams

Patricia

Williams

Dolores

Licensed
Marriage &
Family Therapist
Licensed
Marriage &
Family Therapist
Certified
Substance Use
Disorder
Counselor
Psychologist
Associate
Marriage &
Family Therapist
Certified
Substance Use
Disorder
Counselor
Registered
Substance Use
Disorder
Counselor
Certified
Substance Use
Disorder
Counselor
Licensed Clinical
Social Worker

37
1356616684

A3006108

Yes

1841218492

LMFT 42309

Yes

1194114652

LMFT 14645

Yes

1992287122
1740528645

PSY 7739
AMFT 80280

Yes
Yes

1407237126

C058100618

Yes

1770003071

R1214130915

Yes

1700275104

Aii52480218

Yes

1821454174

LCSW 26155

No

National Provider
ID #

License #

1992269930

R1335740119

Completed
Cultural
Competence
Training?
Yes

1801374624

AMFT 113948

Yes

CENTER POINT
Last Name

First Name

License

Barton

Justin

Breslin

Alexandra

Registered
Substance Use
Disorder
Counselor
Associate
Marriage &
Family Therapist
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Brown

Paulette

Browning

Tom

Fregoso

Anthony

Hallman

Jon

Jupiter

Addie

Katz

Stacey

Krueger

Faith

Lord

Anthony

Marshall

Precious

Moore

Dion

Naeve

Ronald

Owens

Rebecca

38

Certified
Substance Use
Disorder
Counselor
Registered
Substance Use
Disorder
Counselor
Certified
Substance Use
Disorder
Counselor
Certified
Substance Use
Disorder
Counselor
Certified
Substance Use
Disorder
Counselor
Licensed
Professional
Clinical Counselor
Certified
Substance Use
Disorder
Counselor

1831621879

8306

Yes

1063793727

C14751214

Yes

1871153536

R7454

Yes

1376070490

C039000816

Yes

1053523803

8380

Yes

1265930481

7221

Yes

1063926467

Ci07840617

Yes

Registered
Substance Use
Disorder
Counselor
Registered
Substance Use
Disorder
Counselor
Registered
Substance Use
Disorder
Counselor
Certified
Substance Use
Disorder
Counselor
Certified
Substance Use

1376070440

R1269111117

Yes

1285287854

R1347860519

Yes

1336709054

R1358230810

Yes

1427339365

Aii060440918

Yes

1568749648

Aii059970618

Yes
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Ramos

Melvy

Smith

Karl

Smith

Ada

Taylor

Rodney

Taylor

Sushma

Disorder
Counselor
Registered
Substance Use
Disorder
Counselor
Certified
Substance Use
Disorder
Counselor
Licensed
Marriage &
Family Therapist
Licensed
Marriage &
Family Therapist
Licensed
Marriage &
Family Therapist

39

1568900983

R1264730917

Yes

1356621148

9919

Yes

1306067483

LMFT 15644

Yes

1588058697

LMFT 12402

Yes

1275927394

LMFT 24269

Yes

National Provider
ID #

License #

1821483454

R1302680418

Completed
Cultural
Competence
Training?
Yes

1932688033

R1323300918

Yes

1427426527

AMFT 100862

Yes

1023365392

LPCC 3239

No

1699215608

R1295680318

Yes

MARIN TREATMENT CENTER
Last Name

First Name

License

Beggs

Dawn

Cantu

Jonathan

Catan

Hope

Diamond

Joan

Dominguez

Rebecca

Registered
Substance Use
Disorder
Counselor
Registered
Substance Use
Disorder
Counselor
Associate
Marriage &
Family Therapist
Licensed
Professional
Clinical Counselor
Registered
Substance Use
Disorder
Counselor
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Kameron

Alessandra

Laffey

Rajena

Lee

Yuen

Maillo Cabrera

Juan

Moriguchi

Ryoko

Norman

Royal

Obranovich

Cherie

Ogg

Aubrey

Panaligan

Edelyn

Quinones

Jenine

Tocher

Danielle

Associate
Substance Use
Disorder
Counselor
Registered
Alcohol & Drug
Technician
Licensed
Vocational Nurse
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